Stern N, Teicher A, Rosenthal T
Clin Cardiol. 1982 Feb;5(2):125-30. doi: 10.1002/clc.4960050202.
A new alpha- and beta-blocking agent, labetalol, was used to treat 50 hypertensive patients, 34 of them with refractory hypertension. A significant reduction in hypertension was achieved with relatively few adverse reactions. The combination of alpha and beta blockers in labetalol with their mutually opposing characteristics offers an interesting and promising approach to the control of hypertension.
一种新型的α和β受体阻滞剂拉贝洛尔被用于治疗50例高血压患者,其中34例为顽固性高血压患者。该药物在不良反应相对较少的情况下使高血压得到了显著降低。拉贝洛尔中α和β受体阻滞剂的联合以及它们相互拮抗的特性为控制高血压提供了一种有趣且有前景的方法。